Drug Profile
Research programme: Hepatitis B therapeutics - Ark Biosciences
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Ark Biosciences
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Hepatitis-B in China
- 28 Aug 2017 Early research in Hepatitis B in China (unspecified route), (Ark Bioscience pipeline, August 2017)